# Medicxi

> Medicxi is a VC fund in London backing Biotechnology and Health Care. See 61 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 61
- Last investment: Jul 2026
- Lead investor: 54%
- Last fund: Jul 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/medicxi-ventures
- X (Twitter): https://twitter.com/Medicxi
- Website: https://www.medicxi.com/

Medicxi is an investment firm that focuses on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

## Contacts

5 contacts available for Medicxi. Shizune tracks 10 team members at Medicxi. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/medicxi-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 43 | 70% |
| Health Care | 20 | 33% |
| Therapeutics | 19 | 31% |
| Pharmaceutical | 18 | 30% |
| Medical | 11 | 18% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 20 | 33% |
| Series B | 14 | 23% |
| Seed | 7 | 11% |
| Funding Round | 4 | 7% |
| Series C | 3 | 5% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 19 | 31% |
| United Kingdom | 14 | 23% |
| The Netherlands | 3 | 5% |
| China | 2 | 3% |
| France | 2 | 3% |

9 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Giovanni Pericolini | Finance Director & CFO | 0 | https://shizune.co/investors/profile/giovanni-pericolini |
| Kevin Johnson | Co-Founder & Partner | 6 | https://shizune.co/investors/profile/kevin-johnson-8 |
| Mark Boer | Member of the Board of Advisors | 0 | https://shizune.co/investors/profile/mark-de-boer |
| Michele Bauer | Co-Founder & Partner | 3 | https://shizune.co/investors/profile/michele-ollier |
| Trevor Baglin | Venture Partner | 0 | https://shizune.co/investors/profile/trevor-baglin |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Fore Biotherapeutics | We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M | Series D | Jul 07, 2026 |  |
| Altesa | Altesa is a clinical-stage biopharmaceutical company dedicated to accelerating the development of new treatments against age-old threats to human health: high-consequence viral pathogens. | $75M | Series B | Feb 19, 2026 |  |
| D3 Bio | D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path. | $108M | Series B | Dec 09, 2025 |  |
| Fore Biotherapeutics | We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $40.2M | Series D | May 06, 2025 |  |
| Curevo | Curevo is a clinical-stage biotech firm focused on producing next-generation vaccines that brings effectiveness, safety, tolerability, and advanced production capabilities to the market. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90 subject trial). Results are showing a promising safety profile and thedesired immune responses. They are targeting a unique position in the $7B Varicella Zoster Virus vaccine market. | $110M | Series B | Mar 17, 2025 |  |
| Rapt Therapeutics | RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selectivesmall molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development. | $150M | Post-IPO Equity | Dec 23, 2024 |  |
| Ottimo Pharma | Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden. | $140M | Series A | Dec 19, 2024 |  |
| Ottimo Pharma | Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden. |  | Seed | Oct 28, 2024 |  |
| Vicebio | Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses. Vicebio is a biopharmaceutical business that creates innovative vaccinations to prevent potentially fatal respiratory viral infections. | $100M | Series B | Sep 23, 2024 |  |
| Ethyreal Bio | Ethyreal Bio is an early-stage biotechnology company developing precision, mechanism-driven therapies for thyroid diseases with high unmet medical needs. | $41M | Series A | Jun 01, 2024 |  |

10 of 61 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 12 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 9 deals together
- [Longitude Capital](https://shizune.co/investors/profile/longitude-capital) — VC Fund, 8 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 7 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 5 deals together
- [Advent Life Sciences](https://shizune.co/investors/profile/advent-life) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Health Care Investors in United Kingdom](https://shizune.co/investors/health-care-investors-united-kingdom)
- [Biotech Investors in United Kingdom](https://shizune.co/investors/biotech-investors-united-kingdom)
- [Biotech VC Funds in United Kingdom](https://shizune.co/investors/biotech-vc-funds-united-kingdom)
- [Life Science Investors in Switzerland](https://shizune.co/investors/life-science-investors-switzerland)
- [Medical VC Funds in Ireland](https://shizune.co/investors/medical-vc-funds-ireland)
- [Biotechnology VC Funds in Ireland](https://shizune.co/investors/biotechnology-vc-funds-ireland)

## FAQ

### What does Medicxi invest in?

Medicxi invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 61 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Medicxi?

Public channels for Medicxi include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Medicxi?

The team at Medicxi includes Giovanni Pericolini (Finance Director & CFO), Kevin Johnson (Co-Founder & Partner) and Mark Boer (Member of the Board of Advisors), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co